Why did the Medibank share price just crack a new all-time high?

Medibank shares have been in fine form recently…

| More on:
A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medibank Private Ltd (ASX: MPL) share price reached a new all-time high of $3.74 on Tuesday.

And while the private health insurer's shares faded as the day went on, they are still up by a sizeable 8.5% since the start of the month.

Why is the Medibank share price at a record high?

Investors have been bidding the Medibank share price higher this month after it delivered a solid result for FY 2022.

For the 12 months ended 30 June, Medibank reported group revenue up 3.2% year over year to $7,128.5 million and segment operating profit up 11.9% to $638.1 million.

And while its net profit after tax fell due to a $24.8 million loss in net investment income, this didn't stop the Medibank board from increasing its dividend.

What was the reaction?

One leading broker that was impressed was Citi.

In response to the release, the broker retained its buy rating and lifted its price target on the company's shares to $4.00.

So, with the Medibank share price fetching $3.70 currently, Citi sees scope for it to rise a further 8%.

What did the broker say?

Citi was pleased with its performance and outlook. And while it acknowledges that the Medibank share price is not cheap, it sees reasonable value in it. The broker explained:

PHI performing well plus tailwind from investment yields Medibank's PHI business is performing well and we forecast an outlook of largely stable margins paired with reasonable top line growth. Medibank Health is also targeted to grow profit at a rate of at least 15% and higher interest rates should provide a reasonable tailwind for investment income. This keeps us attracted to the Medibank story despite value being reasonable rather than cheap. Largely reflecting marking to market and allowing for higher yields as well as a little more PHI revenue growth, we lift EPS, FY23E: +6%; FY24E: +2%. We retain our Buy call lifting our target price to A$4.00.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »